Arrowhead Pharmaceuticals (ARWR) saw its stock price plummet by 8.28% in pre-market trading on Thursday, following news that its partner Sarepta Therapeutics (SRPT) had sold a substantial portion of its Arrowhead stock holdings. The sell-off by a major stakeholder has triggered concerns among investors, leading to the sharp decline in Arrowhead's share price.
According to a late Wednesday announcement, Sarepta Therapeutics sold approximately 9.3 million common shares of Arrowhead Pharmaceuticals, generating at least $174 million in gross proceeds. Additionally, Sarepta will transfer about 2.7 million Arrowhead shares to satisfy $50 million of a previously announced $100 million milestone payment obligation. This significant reduction in Sarepta's stake in Arrowhead, less than a year after investing $325 million, has contributed to the downward pressure on Arrowhead's stock.
Despite the stock sale, the two companies maintain a collaborative relationship on the development of SRP-1003, an investigational RNA interference therapeutic for the treatment of type 1 myotonic dystrophy. However, the market seems more focused on Sarepta's decision to reduce its Arrowhead holdings. H.C. Wainwright commented that Sarepta's exit at a loss has damaged its credibility, further impacting investor sentiment. As the market digests this unexpected move by a key partner, Arrowhead Pharmaceuticals faces challenges in maintaining investor confidence in the short term.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.